Table 1 The characteristics of patients of the two treatment groups (EBRT + NBT and 3D-CRT) and the univariate analysis of the clinical outcome
Characteristics | Total (%) | EBRT + NBT (%) | 3D-CRT (%) | P value* | 5y OS (%) | P value | 5y LC (%) | P value |
|---|---|---|---|---|---|---|---|---|
Gender | <0.0001 | 0.174 | 0.312 | |||||
Male | 583 (66.0) | 324 (59.4) | 259 (76.4) | 24.5 | 44.7 | |||
Female | 301 (34.0) | 221 (40.6) | 80 (23.6) | 30.8 | 51.9 | |||
Age (years) | 0.003 | 0.291 | 0.591 | |||||
≤65 | 426 (48.2) | 284 (52.1) | 142 (41.9) | 29.9 | 48.3 | |||
>65 | 458 (51.8) | 261 (47.9) | 197 (58.1) | 23.5 | 46.4 | |||
Tumor length | 0.220 | <0.0001 | <0.0001 | |||||
≤5 cm | 409 (46.3) | 261 (47.9) | 148 (43.7) | 31.0 | 52.4 | |||
>5 cm | 475 (53.7) | 284 (52.1) | 191 (56.3) | 22.9 | 42.4 | |||
Tumor location | <0.0001 | 0.233 | 0.581 | |||||
Upper | 329 (37.2) | 174 (31.9) | 155 (45.7) | 26.9 | 49.2 | |||
Middle | 442 (50.0) | 309 (56.7) | 133 (39.2) | 27.8 | 45.6 | |||
Lower | 113 (12.8) | 62 (11.4) | 51 (15.0) | 20.9 | 46.4 | |||
T stage | 0.006 | <0.0001 | <0.0001 | |||||
T1 | 32 (3.6) | 20 (3.7) | 12 (3.5) | 64.1 | 73.1 | |||
T2 | 163 (18.4) | 107 (19.6) | 56 (16.5) | 32.9 | 51.7 | |||
T3 | 305 (34.5) | 164 (30.1) | 141 (41.6) | 31.2 | 53.9 | |||
T4 | 384 (43.4) | 254 (46.6) | 130 (38.3) | 17.6 | 37.7 | |||
N stage | <0.0001 | <0.0001 | ||||||
N0 | 461 (52.1) | 338 (62.0) | 123 (36.3) | 32.6 | 53.2 | |||
N1 | 423 (47.9) | 207 (38.0) | 216 (63.7) | 20.2 | 40.0 | |||
AJCC stage | <0.0001 | <0.0001 | <0.0001 | |||||
I | 28 (3.2) | 20(3.7) | 8 (2.4) | 72.3 | 74.5 | |||
IIa | 280 (31.7) | 195 (35.8) | 85 (25.1) | 36.0 | 56.6 | |||
IIb | 55 (6.2) | 22 (4.0) | 33 (9.7) | 29.3 | 35.2 | |||
III | 521 (58.9) | 308 (56.5) | 213 (62.8) | 19.2 | 41.1 | |||
Radiation dose | <0.0001 | 0.263 | 0.658 | |||||
≤60Gy | 321 (36.3) | 91 (16.7) | 230 (67.8) | 22.9 | 44.7 | |||
>60Gy | 563 (63.7) | 454 (83.3) | 109 (32.2) | 29.0 | 48.6 | |||